A new special edition and a new event in Copenhagen – This is happening at Life Science Sweden 2024

The new year brings new features for the readers of Life Science Sweden.

Galderma

MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.

Topp 50: Här är Sveriges högst rankade medicinforskare

Kaj Blennow, Tomas Hökfelt och Anders Björklund toppar listan över de svenska forskare som citeras mest frekvent inom det medicinska forskningsfältet. Se de 50 ...

HAB Nicolai Johannsen

How to optimise your liquid handling results

In dispensing or pipetting applications in laboratory automation, it is important to obtain reliable results, which are analysed by calculating the accuracy and...

ZEISS Insights: Measurement of bone plates and screws

Get free access to technical paper.

Try arivis for free

30-day free trial offers a number of benefits.

“Research is always a lot of failures and a few successes”

Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessibl...

GSK pays 2.2 billion dollars to settle Zantac lawsuits

British drugmaker Glaxo Smith Kline, GSK, has struck a 2.2 billion dollar settlement, thereby resolving a vast majority of the liability cases pending against t...

How to transport hydrogen - the BionicHydrogenBattery

Have you ever wondered how hydrogen should be transported and stored safely. Well, here is a solution for all who is interested in making a true infrastructure work.

Italian pharmaceutical company buys rights to immunotherapy from Sanofi

Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).

Fast Optical Sectioning of Developing Organisms and Tissue Microstructures

ZEISS Lattice SIM 3 exploits the full potential of the SIM Apotome technology.

Lilly recruits top Swedish researcher in Alzheimer´s

One of Sweden's leading Alzheimer's researchers, Oskar Hansson, has been recruited by pharma giant Eli Lilly and will be moving to the USA.

Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”

It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic hav...

Medivir CEO on upcoming study: ”It's about working together with others”

Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks appr...

Samuel Lagercrantz: We are currently seeing medical breakthroughs in these areas

Samuel Lagercrantz, Editor in Chief of Life Science Sweden, lists three medical fields in which we are currently seeing major breakthroughs and two fields in wh...

“I am driven by the desire to develop a product that can be sold worldwide”

Ranked number one in the world by the WHO in diarrhoea research and soon in phase III studies for its vaccine candidate – Scandinavian Biopharma is rushing forw...

“Life science is important on a personal level”

From the High Coast to the Government Offices. Jeanette Edblad is a native of Ångermanland, and since September last year, she has been Head and Coordinator of ...

Are you curious about volume imaging for very large samples?

Exciting ZEISS Webinar!

Topp 20-listor: Sveriges främsta forskare inom molekylär- och mikrobiologi

Mathias Uhlén, Staffan Normark, Joakim Dillner och Carl-Henrik Heldin är namnen som återfinns högst på listorna över Sveriges mest citerade forskare inom mikrob...

AstraZeneca to use American AI platform for cancer trials

In a collaboration AstraZeneca will use an AI model from Israeli-American biotech Immunai to streamline its clinical trials in cancer.

Learn from Speakers from Leading MedTech Companies

Watch the recordings from ZEISS Quality Innovation Days whenever it suits you.

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."